These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38249987)

  • 21. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
    Ramakrishnan S; Jeffers H; Langford-Wiley B; Davies J; Thulborn SJ; Mahdi M; A'Court C; Binnian I; Bright S; Cartwright S; Glover V; Law A; Fox R; Jones A; Davies C; Copping D; Russell RE; Bafadhel M
    Lancet Respir Med; 2024 Jan; 12(1):67-77. PubMed ID: 37924830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
    Ni H; Htet A; Moe S
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT.
    Francis NA; Gillespie D; White P; Bates J; Lowe R; Sewell B; Phillips R; Stanton H; Kirby N; Wootton M; Thomas-Jones E; Hood K; Llor C; Cals J; Melbye H; Naik G; Gal M; Fitzsimmons D; Alam MF; Riga E; Cochrane A; Butler CC
    Health Technol Assess; 2020 Mar; 24(15):1-108. PubMed ID: 32202490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical investigation on the related factors for the application of systemic glucocorticoids in patients with acute exacerbation of chronic obstructive pulmonary disease with carbon dioxide retention].
    Jiao W; Zhang W; Zhang C; Liu Z; Gan Y; Peng Z; Yan G; Deng X; Xue Q; Wu J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Sep; 32(9):1061-1066. PubMed ID: 33081891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
    Doherty DE; Tashkin DP; Kerwin E; Knorr BA; Shekar T; Banerjee S; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():57-71. PubMed ID: 22334769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial.
    Verberkt CA; van den Beuken-van Everdingen MHJ; Schols JMGA; Hameleers N; Wouters EFM; Janssen DJA
    JAMA Intern Med; 2020 Oct; 180(10):1306-1314. PubMed ID: 32804188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts.
    Fawzy A; Putcha N; Paulin LM; Aaron CP; Labaki WW; Han MK; Wise RA; Kanner RE; Bowler RP; Barr RG; Hansel NN;
    Respir Res; 2018 Jan; 19(1):20. PubMed ID: 29373977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
    van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
    Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-Related Exacerbations.
    Fuoco MJ; Mularski RA; Wu B; Moretz C; McBurnie MA; Stanford RH; Crawford P; Gratie D; Salas B
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2755-2767. PubMed ID: 34675501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infant behavioral state and stool microbiome in infants receiving Lactocaseibacillus rhamnosus GG in formula: randomized controlled trial.
    Shulman RJ; Chichlowski M; Orozco FG; Harris CL; Wampler JL; Bokulich NA; Berseth CL
    BMC Pediatr; 2022 Oct; 22(1):580. PubMed ID: 36207675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III, two arm, multi-centre, open label, parallel-group randomised designed clinical investigation of the use of a personalised early warning decision support system to predict and prevent acute exacerbations of chronic obstructive pulmonary disease: 'Predict & Prevent AECOPD' - study protocol.
    Kaur D; Mehta RL; Jarrett H; Jowett S; Gale NK; Turner AM; Spiteri M; Patel N
    BMJ Open; 2023 Mar; 13(3):e061050. PubMed ID: 36914185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.
    Paggiaro PL; Dahle R; Bakran I; Frith L; Hollingworth K; Efthimiou J
    Lancet; 1998 Mar; 351(9105):773-80. PubMed ID: 9519948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort.
    Yohannes AM; Mülerová H; Lavoie K; Vestbo J; Rennard SI; Wouters E; Hanania NA
    J Am Med Dir Assoc; 2017 Nov; 18(11):955-959.e6. PubMed ID: 28733182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overuse of long-acting β
    Brunton SA; Hogarth DK
    Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.
    Fawzy A; Putcha N; Aaron CP; Bowler RP; Comellas AP; Cooper CB; Dransfield MT; Han MK; Hoffman EA; Kanner RE; Krishnan JA; Labaki WW; Paine R; Paulin LM; Peters SP; Wise R; Barr RG; Hansel NN;
    Chest; 2019 Mar; 155(3):519-527. PubMed ID: 30593776
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.